© Inserm/Delapierre Patrick
To find out more about the experiments to be conducted by Thomas Pesquet, read the complete file prepared by Inserm’s magazine:
Espace – L’Inserm en orbite (Space – Inserm in orbit) (Science&Santé No. 27, only in French)
Listen to the interview with Thomas Pesquet conducted on behalf of Inserm at the Paris Airshow (a coproduction of Inserm/CNES):
For your information, Inserm, a scientific partner of the flight operated by ESA, is holding a citizens’ conference, which will be attended by the researchers involved and Claudie Haigneré:
Conquête spatiale et innovation médicale (Conquest of space and medical innovation): 26 November, 7:00-8:30 pm Cité des sciences et de l’industrie de Paris, Museum de Toulouse (simultaneous production, as part of Futurapolis)
Follow on @InsermLive
3 Inserm laboratories involved in 4 experiments:
The research team will study space sickness and its relationship with travel sickness. Technologically, the laboratory is working with the Bodycap company on miniaturised actigraph and temperature sensors, and the corresponding analytical software. These sensors will be loaded into a smart vest which will be worn by Thomas Pesquet.
Inserm Unit 1075, “Mobilities: Attention, Orientation and Chronobiology” (Caen)
+33 (0)2 31 06 81 32
– This laboratory will study changes to bone due to space flight, and recovery on returning to earth.
– A second experiment, conducted in vitro, will be aimed at understanding why in space, bone marrow precursor cells differentiate into adipocytes at the expense of osteocytes, the main cause of reduced bone formation and hence of bone loss.
Inserm Unit 1059, “Integrative Biology of Bone Tissue”
+33 (0)4 77 42 18 57
Space flights are good models for the study of accelerated ageing, in that some preliminary data indicate that arterial stiffness may increase by an equivalent of approximately 10 years during short space flights. Changes related to microgravity will be studied with the help of specially developed flexible sensors (in collaboration with ESIEE Paris and the ESYCOM laboratory
Inserm Unit 970 PARCC
+33 (0)1 56 09 39 66
Inserm is launching its first accelerator of technological research according to the objective that is part of the Institute's strategic plan 2016-2020. This first “Biomedical Ultrasound” ART will be dedicated to research and the use of ultrasound in medicine, particularly in the ...
Paris, March 21st, 2017 – Stimunity, Institut Curie and Inserm are pleased to announce that the company has signed an exclusive worldwide license agreement on two key patents that cover Stimunity’s core technology VLP-cGAMP to develop new drugs in immuno-oncology. ...